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Abstract
Acute leukaemias are commonly caused by mutations that corrupt the transcriptional circuitry of haematopoietic stem/
progenitor cells. However, the mechanisms underlying large-scale transcriptional reprogramming remain largely unknown.
Here we investigated transcriptional reprogramming at genome-scale in mouse retroviral transplant models of acute myeloid
leukaemia (AML) using both gene-expression profiling and ChIP-sequencing. We identified several thousand candidate
regulatory regions with altered levels of histone acetylation that were characterised by differential distribution of consensus
motifs forkeyhaematopoietic transcriptionfactors includingGata2,Gfi1 and Sfpi1/Pu.1.In particular, downregulationof Gata2
expression was mirrored by abundant GATA motifs in regions of reduced histone acetylation suggesting an important role in
leukaemogenic transcriptional reprogramming. Forced re-expression of Gata2 was not compatible with sustained growth of
leukaemic cells thus suggesting a previously unrecognised role for Gata2 in downregulation during the development of AML.
Additionally, large scale human AML datasets revealed significantly higher expression of GATA2 in CD34+ cells from healthy
controls compared with AML blast cells. The integrated genome-scale analysis applied in this study represents a valuable and
widely applicable approach to study the transcriptional control of both normal and aberrant haematopoiesis and to identify
critical factors responsible for transcriptional reprogramming in human cancer.
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Introduction
Mutations in transcriptional and epigenetic regulators are a
recurring theme in acute leukaemias. These mutations arise in
haematopoietic stem/progenitor cells (HSPCs) and are thought to
promote leukaemia by deregulating transcriptional programs
controlling proliferation, differentiation and cell death [1,2]. In
about half of all acute leukaemia patients, specific chromosomal
translocations are found that lead either to the creation of aberrant
fusion-proteins with oncogenic potential or to the ectopic expression
of proto-oncogenes [3,4]. The majority of leukaemogenic translo-
cations in acute myeloid leukaemia (AML) affect genes involved in
transcriptional regulation or chromatin modification, thus high-
lighting the importance of deregulated transcriptional programs.
Mouse model systems using retroviral transduction of oncogenic
fusion proteins recapitulate many aspects of the human disease
and therefore represent valuable tools to dissect the molecular
mechanisms causing AML [5]. Mixed Lineage Leukaemia (MLL) and
Monocytic Leukaemia Zinc Finger (MOZ) fusion proteins have both
been shown to subvert HSPCs into AML leukaemia cells in
retroviral transplant mouse models [6,7,8]. Both proteins interact
with the cellular epigenetic machinery, conferring either histone
methyl transferase [9] or histone acetyl transferase activity [10].
MLL- and MOZ-fusion proteins are both thought to promote the
leukaemic phenotype at least in part by mediating ectopic
expression of abdominal HoxA-genes [11,12,13,14,15]. MLL
fusion proteins are considered potent oncogenes and MLL-ENL
causes leukaemia with relatively short latency in retroviral bone
marrow transplant models [6]. AML caused by MOZ-TIF2 is also
associated with a poor prognosis; however, the retroviral models
have a longer latency [7] suggesting some differences within the
mechanisms that drive transcriptional reprogramming.
Although, much has been learnt about the role of single
transcription factors in both normal haematopoiesis and leukae-
mogenesis [16,17], only the recent advent of array- and
sequencing-based high-throughput technologies has enabled
functional investigations on a genome-wide scale. For example,
binding sites have been mapped for the stem cell regulator Scl in
normal HSPCs [18] as well as the PML-RARA oncoprotein in
promyelocytic leukaemia cells [19]. However, to improve our
understanding of how specific leukaemogenic mutations corrupt
entire transcriptional programmes, genome-wide studies need to
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note, retroviral transduction models generate leukaemias with
essentially identical immunophenotypes following initial transduc-
tion of either haematopoietic stem-cells (HSCs), common myeloid
progenitors (CMPs) or granulocytic/monocytic-restricted progen-
itors (GMPs) [6]. This suggests that genome-wide comparisons of
gene expression and ChIP-sequencing profiles between normal
HSPCs and leukaemic cells might provide novel hypotheses about
globally acting processes that underlie leukaemogenic transcrip-
tional reprogramming.
In this study, we used this approach to assess and compare
transcriptional reprogramming in two leukaemia progression
models, based on established MLL-ENL [6] and MOZ-TIF2
[7,20] AML mouse model systems. The experiments were
designed to allow us to answer the following questions: (i) To
what extent are leukaemia initiation programmes induced by
MLL-ENL and MOZ-TIF2 distinct? (ii) Is progression to frank
leukaemia for both oncogenes accompanied by convergence
towards a shared transcriptional program? (iii) What are the
advantages of combining profiling for gene-expression with ChIP-
Seq compared to gene-expression alone? (iv) Does histone
acetylation ChIP-Seq represent a useful tool to reliably identify
alterations in candidate regulatory regions associated with
transcriptional reprogramming at genome-wide scale? (v) Does
bioinformatic motif analysis of altered candidate regulatory
regions represent a potential avenue into identifying the regulatory
processes that underlie transcriptional reprogramming?
Results
Mouse model systems to study transcriptional
reprogramming during AML development
To study the genome-wide dynamics of leukaemogenic tran-
scriptional reprogramming, we used two established transplantable
AML mouse models based on retroviral transduction of normal
bone-marrow progenitor cells with MLL-ENL or MOZ-TIF2
fusion proteins, respectively. Both mouse models are characterized
by an initially longer latency, which is rapidly shortened following
re-transplantation of the resultant AML-cells into secondary and
tertiary recipients [6,7]. Importantly, primary transduced pre-
leukaemic cells can be cultured in vitro as interleukin 3 (IL3)
dependent cell lines. These in vitro cultured cells maintain the initial
long-latency when transplanted into irradiated recipients and thus
represent a surrogate model for the pre-leukaemic ‘‘initiation’’
phase of AML [7]. By contrast, frank leukaemic cells maintain their
short latency, even if exposed to periods of IL3-culturing prior to
transplantation [7] which allowed us to standardise sampling
conditions by overnight culture in IL3.
To serve as baseline comparators for our analysis of leukaemia
progression, we elected to sample two controls: (i) the lineage
negative/c-kit positive (lin
-/kit
+) compartment of wild-type bone-
marrow mononuclear cells (WT) representing the target cells
transduced by the leukaemogenic retroviruses [6], and (ii) the Factor-
Dependent Cells Patterson-Mix (FDCP-mix) cell-line,a non-transformed
IL3 dependent murine progenitor cell-line, capable of haematopoi-
etic multi-lineage differentiation and, importantly, lacking leukae-
mogenic potential[21]. Wereasoned that use oftheFDCP-mixcell-
line as an additional baseline control would allow us to correct for
expression changes associated with in vitro culture in IL3 used for
‘‘pre-leukaemic’’ and ‘‘leukaemic’’ cells. As summarized in
Figure 1A, transcriptional programmes were therefore monitored
at three different time points: at ‘baseline’ (for WT and FDCP-mix),
following ‘initiation’ (ME-I and MT-I) and after ‘progression to the
frank leukaemic state (ME-L and MT-L).
Pre-leukaemic MOZ-TIF2 gene-expression profiles cluster
with non-leukaemic, whereas MLL-ENL is more similar to
leukaemic samples
To monitor global expression changes during leukaemia
progression for both MLL-ENL and MOZ-TIF1, we performed
gene expression profiling for three biological replicates each of the
lin
-/kit
+ bone marrow (WT), FDCP-mix (FDCP), MLL-ENL
initiation (ME-I), MOZ-TIF2 initiation (MT-I), MLL-ENL pro-
gression (ME-L) and MOZ-TIF2 progression (MT-L) samples.
20,759 of the 45,281 probes present on the array were expressed in
at least one of our samples (Figure 1B). As expected, unsupervised
hierarchical clustering and Gene Expression Dynamics Inspector (GEDI)
maps of all expressed transcripts showed a clear separation of the
two baselines and the two leukaemia samples (Figure 1D).
Interestingly though, the gene-expression profile of MOZ-TIF2-
inititation (MT-I) was closer to the non-leukaemic baseline samples
WT and FDCP, whereas MLL-ENL-initiation (ME-I) was highly
similar to the leukaemic samples MLL-ENL-L (ME-L) and MOZ-
TIF2-L (MT-L). Further analysis of differential expression in six
relevant pair-wise comparisons (summarised in Table S1 in
Supporting Information S1) revealed more changes upon initiation
but less at progression in MLL-ENL, compared to MOZ-TIF2
(Figure 1C), consistent withthe differential clustering of the two pre-
leukaemic samples.
To validate in silico the biological significance of the leukaemic
clustering of ME-I, ME-L and MT-L, we performed Gene Set
Enrichment Analysis (GSEA), based on a comparison with the two
baselines (WT and FDCP-mix). Significant enrichments (FDR
,10%) were found for curated gene-sets known to be associated
with leukaemogenesis, such as up-regulated in HoxA9 and MLL-
fusions or modified by Retinoid Acid Receptor Alpha (RARA) [22,23,24]
(Figure S1 A,B and C in Supporting Information S1). Taken
together, comprehensive gene-expression profiling analysis implies
that leukaemogenic transcriptional reprogramming occurs faster
with MLL-ENL than MOZ-TIF2. Moreover, while the transcrip-
tional status of the ‘initiation’ phase is distinct for the two different
oncogenes, leukaemic progression of MOZ-TIF2 samples results in
a transcriptional profile much closer to the MLL-ENL samples.
Transcriptional downregulation is a common feature of
MLL-ENL and MOZ-TIF2 leukaemia models
Both fusion-proteins MLL-ENL and MOZ-TIF2 are thought to
induce leukaemogenic transformation at least in part by activating
abdominalHoxA-clustergenes.However,delayedacquisitionofafull
leukaemic expression profile seen with MOZ-TIF2 suggests that
additional down-stream effectors/collaborators are required and
occur early or late with the MLL-ENL and MOZ-TIF2 oncogenes,
respectively.Ofnote,simultaneousavailabilityoftimecoursedatasets
for both MLL-ENL and MOZ-TIF2 provided an opportunity to
identify some of these putative effectors by intersecting the dif-
ferentially expressed genes of the ‘‘baseline’’/‘‘initiation’’ compari-
son for MLL-ENL with the ‘‘initiation’’/‘‘progression’’ comparison
for MOZ-TIF2. This allowed us to identify 49 upregulated and 111
downregulated probes (corresponding to 40 and 88 genes), which
represent to a novel candidate gene set associated with development
of full leukaemia in these two AML mouse models (Figures S3, S4
and Table S2 in Supporting Information S1).
Common downregulation in the ME-I, ME-L and MT-L
samples was also readily observed in the GEDI maps (see
arrowheads in Figure 1D). 17 out of 23 genes in the repressed
GEDI region overlapped with the shared repressed gene-set derived
from the analysis of differentially expressed genes, thus underlining
the consistency of our results using two independent bioinformatic
Global Transcriptional Reprogramming in AML
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16330Figure 1. Gene-expression dynamics during MLL-ENL and MOZ-TIF2 mediated reprogramming. A). Diagram outlining how samples
collected for expression profiling and ChIP-sequencing constitute a leukaemia progression model. B) Flow chart of gene-expression analysis. 20,759
of the 45,281 probes represented on the array (45.8%) were found to be expressed in at least one sample (detection p-value .0.01). Differential
expression analysis was performed for six representative pair-wise comparisons, as summarized in Table S1 in Supporting Information S1. Non-
redundant, differentially expressed probes (nr-de) were determined as outlined in Figure S2 in Supporting Information S1: 857 probes for MLL-ENL
(ME-nr-de probes) and 2,608 for MOZ-TIF2 (MT-nr-de probes) corresponded to 3,075 non-redundant probes differentially expressed in at least one of
the transitions (all-nr-de probes). C) Bar-charts of differentially expressed probes in six relevant pair-wise comparisons. Y-axis shows the total number
of differentially expressed probes, as outlined in Table S1 in Supporting Information S1, for the ‘‘Initiation’’ (WT/FDCP vs ME-I/MT-I) and the
‘‘Progression’’ to overt leukaemia (ME-I/MT-I vs ME-L/MT-L). D) Unsupervised hierarchical clustering (UHC) correlates with Gene Expression Dynamics
Inspector (GEDI) maps. All 20,759 expressed probes were clustered, as shown in the dendrogram on the top of the figure, and dynamic expression
changes visualized with GEDI maps. Mean expression values of probes with similar dynamic patterns are condensed by self organizing maps in
expressed (red) and repressed (blue) tiles and proximity of adjacent tiles indicates similar dynamics [60]. UHC and GEDI identified a ‘non-leukaemic’
cluster, containing the WT, FDCP and MT-I samples, and a ‘leukaemic’ cluster, comprising the ME-I, ME-L and the MT-L samples. A group of co-
ordinately downregulated probes seen in the ME-I, ME-L and MT-L samples is indicated by white arrowheads.
doi:10.1371/journal.pone.0016330.g001
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as probes derived from the shared repressed GEDI region are
displayed in clustered heat-maps (Figure S4 in Supporting
Information S1) and listed as 40, 88 and 23 unique genes,
respectively (Table S2 in Supporting Information S1). Interestingly,
key haematopoietic transcription factors such as Gata2, Gfi1b and
Zfpm1/Fog, were found in this commonly repressed gene-set. In
summary, global analysis provided evidence that transcriptional
downregulation is a common feature associated with full leukaemic
transition in both AML mouse models.
Dynamic transcriptional regulation of hematopoietic
stem/progenitor cell transcription factors during
leukaemogenic progression
Our finding of downregulated expression of Gata2, Gfi1b and
Zfpm1/Fog during leukaemic progression prompted us to
investigate in more detail transcription factor gene expression
patterns to identify candidate regulators of leukaemogenic
transcriptional reprogramming. 121 genes functionally annotated
as DNA-binding transcription factors were differentially expressed
in comparisons involving MLL-ENL and/or MOZ-TIF2 time
courses. These included several HoxA genes as well as 19
transcription factors known to function as regulators of HSPCs
[25]. Unsupervised hierarchical clustering using these 19 genes
generated the same partition observed above into ‘non-leukaemic’
and ‘leukaemic’ clusters with HSPC-TFs subdivided into gene-
clusters of repression and activation (Figure 2A). The repression
cluster could be further separated into genes repressed in both
MLL-ENL and MOZ-TIF2 after progression to frank leukaemia
(Klf1, Gata2, Gfi1b, Zfpm1/Fog), repression in MOZ-TIF2 only
(Cebpe, Fli1), repression in MLL-ENL only (Tal1, Eto2, Runx1)
and more variable patterns (Cebpa, Ets1, Meis1, Pbx1). The
cluster of activation (Lmo2, Ets2, Klf2, Gfi1, Lyl1, Sfpi1/Pu.1)
showed fairly homogenous activation separating the WT/FDCP/
MT-I from the ME-I/ME-L/MT-L samples.
Having generated genome-wide histone acetylation datasets by
ChIP-Seq in parallel to our gene-expression profiles, we next
investigated whether alterations in steady state mRNA levels were
accompanied by corresponding changes in levels of histone
acetylation. As we and others have previously reported, cell-type
specific regulatory regions can be identified by differential
enrichment of H3K9ac [26,27]. Activation of the abdominal
HoxA-cluster genes is known to contribute to the leukaemogenic
phenotype in our AML models. Increased expression of HoxA
genes was paralleled by increased H3K9ac marks as shown in
Figure 2B. Beyond the specific example of the HoxA locus,
dynamic changes of histone acetylation closely followed the
dynamics of transcriptional changes (see Figures S5, S6 and S7
in Supporting Information S1 for example plots of HSPC-TF loci).
Changing levels of acetylation marks were not only seen in
promoter-regions but also observed at known and potentially new
distal cis-regulatory elements, as exemplified for Gata2 and Klf2 in
Figure 2C and 2D. Taken together, we hypothesize that
leukaemogenic progression in MLL-ENL and MOZ-TIF2 AML
models is associated with altered expression of HSPC-TFs which,
in turn, is accompanied by corresponding changes in H3K9ac
profiles at their candidate regulatory regions.
Over-representation of consensus binding motifs for
differentially expressed HSPC transcription factors within
the most variable H3K9ac candidate regulatory regions
We next asked whether global motif content analysis of dif-
ferentially acetylated regions would allow us to draw conclusions
about which transcription factors might be relevant for genome-
wide transcriptional reprogramming. To this end, peaks of enriched
H3K9ac were identified for all 12 ChIP-Seq samples (2 biological
replicates for each of our samples) resulting in a total number of
128,354 candidate regulatory regions that were identified in at least
one sample. This is in line with the approximately 100,000 regions
of open chromatin thought to be characteristic for mammalian cell
types [28]. We next determined the relative number of CHIP-Seq
reads for each of these 128,354 regions in each sample, which
demonstrated high reproducibility of biological replicates (see
Figure 3A). By contrast, when comparing samples corresponding
to different stages such as baseline and leukaemia initiation stages
(FDCP v. ME-I), substantial numbers of peaks showed altered levels
of histone acetylation (Figure 3B).
To identify those regions with statistically significant changes of
histone acetylation that parallel our gene expression analysis, we
partitioned the ChIP-Seq peak datasets into WT, FDCP and MT-
I on the one hand and ME-I, ME-L and MT-L on the other hand,
in line with the major partition identified by clustering analysis of
gene expression profiles. Peak-regions with significant changes in
H3K9ac were determined by high-dimensional T-test analysis,
defining the most variable candidate regulatory regions. Of note,
many more peaks showed reduced levels of histone acetylation
than an increase (Fig 3C) consistent with the predominance of
downregulation observed in the gene expression profiling analysis.
To identify transcription factors that may be involved in this
global reorganization of chromatin, we next explored the
distribution of consensus binding motifs for differentially expressed
HSPC-TFs across the most variable H3K9ac peak-regions (see
Material and Methods). We focused this analysis on motifs for
Gata2 and Gfi1/Lyl1/Sfpi1 which were down- and up-regulated
respectively across the major partition (WT/FDCP/MT-I v ME-
I/ME-l/MT-L) and also included motifs for Cebpa and Meis1 as
controls because expression of those two factors did not correlate
with this partition (Figure 3D). When we determined the expected
and observed motif-occurrences for these six factors within
differentially acetylated regions defined above, consensus sites for
the two controls Cebpa and Meis1 occurred in expected
frequencies. By contrast, motifs for all differentially expressed
factors except Lyl1 showed highly significant over and/or under-
representation (Figure 3E). Of particular interest, the consensus
motifs for Gata2 and Sfpi1/Pu.1 were significantly over-/under-
represented respectively in regions with reduced histone acetyla-
tion, which was completely consistent with the sharp downregu-
lation of Gata2 and upregulation Sfpi1/Pu.1 expression at this
transition. Taken together, the distribution of consensus binding
motifs within candidate regulatory regions with significant changes
of histone acetylation revealed that differentially expressed HSPC
TFs such as Gata2 and Sfpi1/Pu.1 may play a role in
transcriptional reprogramming.
Gata2 over-expression inhibits expansion of MLL-ENL
transduced cells
Integrated analysis of gene-expression and ChIP-Seq profiling
datasets suggested a role for Gata2 downregulation during the
development of AML in our mouse model system. To identify a
potential functional role for Gata2 downregulation, we re-
expressed Gata2 in MLL-ENL transduced cells. Expression
vectors with IRES-dependent GFP-expression were used to
monitor the proportion of GFP-positive cells in competitive
proliferation assays performed in liquid and semi-solid conditions.
We compared the effect of the empty vector Mscv-PIG (PIG) with
full length Gata2 (Gata2) and a Gata2 deletion mutant (DGata2)
(see Figure S8A in Supporting Information S1), which only
Global Transcriptional Reprogramming in AML
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16330Figure 2. Dynamic changes of HSPC transcription factors during MLL-ENL and MOZ-TIF2 induced reprogramming. A) Hierarchical
clustering of 19 dynamically expressed HSPC transcription factors. For comparison, dynamic expression changes of 5 abdominal HoxA-cluster genes
are depicted as a heatmap at the bottom of the figure but were not included for the clustering analysis. Clusters of repression and activation could be
distinguished and are separated by a horizontal dotted red line. B) Dynamic changes of histone H3K9 acetylation (H3K9ac) at the HoxA-cluster gene-
locus. ChIP-Seq traces are displayed on the UCSC genome browser for one representative biological replicate of the six conditions under
investigation (WT, FDCP, MT-I, MT-L, ME-I, ME-L). C) Dynamic changes of H3K9ac at the Gata2 gene-locus. Down-regulation of Gata2 expression is
Global Transcriptional Reprogramming in AML
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zinc-fingers required for DNA-binding (see Figure S8B in
Supporting Information S1). Both constructs produced the
expected RNA and protein products see Figure S8C, D and E
in Supporting Information S1).
In liquid-culture, GFP-positive cells over-expressing Gata2
demonstrated a competitive disadvantage by comparison with
the GFP-negative cell fraction and showed highly reduced growth-
kinetics when compared with cells transduced with the empty
vector and the DGata2 constructs (Figures 4A and B). In
paralleled by reduced acetylation marks. D) Dynamic changes of H3K9ac at the Klf2 gene-locus. Up-regulation of Klf2 expression is paralleled by
increased acetylation marks.
doi:10.1371/journal.pone.0016330.g002
Figure 3. Over-representation of consensus binding motifs from differentially expressed HSPC transcription factors within most
variable H3K9ac candidate regulatory regions. A) Kernel Density Estimation Plots (heat-maps) of relative H3K9ac peak-scores from biological
replicates used for analysis of leukaemogenic progression in MLL-ENL. Peak scores are depicted as colour-coded heat-maps for the two FDCP
biological replicates. Most datapoints lie on a diagonal suggesting good correlation between biological replicates. B) Heat-maps of relative H3K9ac
peak-scores for the FDCP/ME-I ‘Initiation’ comparison as well as depiction of ‘‘stable’’ and ‘‘variable’’ regions (T-test: p#0.05). Variable regions were
clearly divided into enriched (above 45u axis) and deprived (below 45u axis) regions. C) Summary of dynamically changing H3K9ac candidate
regulatory regions for the wt/FDCP/MT-I v. ME-I/ME-L/MT-L comparison. D) Expression profile for selected HSPC TFs across the wt/FDCP/MT-I v. ME-I/
ME-L/MT-L comparison (derived from Fig. 2A). E) Observed and expected frequencies of 6 consensus-motifs in most variable H3K9ac candidate
regulatory regions from C). Significantly increased and reduced peak-regions were used for the detection of differentially distributed motifs using
bootstrap analysis with 1000 sets of background sequences (see methods). Significant under/over-representation was defined by a Z-score of #23o r
$+3 (indicated by a *).
doi:10.1371/journal.pone.0016330.g003
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16330Figure 4. Gata2 over-expression interferes with cell-cycling and is incompatible with sustained proliferation of MLL-ENL
transduced cells. A) Fraction of GFP-positive cells monitored in a competitive proliferation assay performed in liquid culture over a time-course of 9
days. ME-I cells were transduced with pMSCV-Pgk-Puro-IRES-GFP (PIG), pMSCV-Gata2-Pgk-Puro-IRES-GFP (Gata2) and pMSCV-DGata2-Pgk-Puro-IRES-GFP
(DGata2). Vector constructs are outlined in Figure S9A and B in Supporting Information S1. X-axis depicts days after transduction, y-axis the GFP-
positive cell-fraction (% of total viable cells). GFP-positive and GFP-negative cells of each sample were analysed together without prior FACS-sorting.
Results from two independent experiments (mean 6 SD) are shown. Subsequent analysis (Figure 4D) was performed 36 hours after transduction
(indicated by the dotted line). B) Growth curves show that Gata2 overexpression is incompatible with sustained proliferation of ME-I cells. X-axis
depicts days after transduction, y-axis the total GFP-positive cell-number (in millions) determined from the GFP-positive fraction and the total number
Global Transcriptional Reprogramming in AML
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a near complete failure of colony formation in semi-solid
conditions, whereas the number of GFP positive and negative
colonies was comparable for the negative controls (Figure 4C and
E). To investigate the proliferation defect mediated by Gata2 in
more detail, we performed cell-cycle and apoptosis analysis
36 hours after transduction. By analyzing GFP-positive and
GFP-negative cells from the same sample in parallel, we were
able to perform comparative analysis both within and across
different samples. Consistent with the proliferation assays, Gata2
over-expressing samples showed an increase of cells in G0/G1-
and a corresponding decrease in S/G2/M-phase, compared to the
internal and external controls (Figure 4D). Importantly, 293T cells
showed no obvious differences in growth or appearance when
transfected with the same Gata2 expression or the two control
constructs (PIG and DGata2). We have therefore no reasons to
assume that high-level expression of Gata2 is non-specifically toxic
to transduced cells. Moreover, we did not observe any significant
effect on apoptosis by AnnexinV staining and no increase of
quiescence by Ki67-staining 36 hours after infection of MLL-ENL
cells (see Figure S9 in Supporting Information S1). In summary,
over-expression of Gata2 is incompatible with sustained prolifer-
ation of MLL-ENL transduced cells consistent with a model
whereby downregulation of Gata2 plays a role during the early
stages of leukaemogenic reprogramming.
Downregulation of GATA2 in human AML
Any potential involvement of GATA2 downregulation in the
development of haematological disorders remains as yet unclear
[29,30]. However, when we analysed published gene-expression
datasets, two collections of 285 and 33 AML patients showed
higher levels of GATA2 gene-expression in CD34+ cells from
healthy controls compared with AML blast cells [31,32]
(Figure 4F). Similar levels of GATA2 were found in all subtypes
of AML and analysis of two additional datasets [33,34]
demonstrated that AML with minimal differentiation (FAB
AML-M0) showed the lowest levels of GATA2 (Figure 4G). This
latter observation suggests that while GATA2 expression is
downregulated during normal myeloid differentiation, low GATA2
expression in AML cells is unlikely to be simply related those
myeloid differentiation steps that can still occur in leukaemic cells
as it already occurs in the phenotypically most immature AML
samples. Publicly available gene-expression datasets therefore
corroborate a potential role for GATA2 downregulation in the
development of human AML.
Discussion
New genome-wide experimental approaches are widely reported
as the ‘next generation’ of technologies that will revolutionise our
understanding of cancers such as acute leukaemia. However, this
goal is substantially complicated by the fact that acute leukaemias
are caused by heterogeneous genetic and epigenetic events, which
can occur at multiple levels during the dynamic progression from a
premalignant state to frank leukaemia. For example, while genome-
wide mapping of MLL-AF4 binding events identified stem cell
regulators as prevalent target genes [35], little is known about the
dynamic nature of global transcriptional reprogramming required
for initiation and subsequent progression to the full leukaemic
phenotype. Importantly, a focus on transcriptional reprogramming
has the potential to identify shared aspects of transcriptional
dysregulation and thus reduce the complexity and heterogeneity of
diverse oncogenic events to a small number of specific pathways for
exploration as novel disease classifiers and/or potential drug targets.
Studying the initiation or early progression of diseases such as
AML is not feasible in human patients. However, mouse models of
AML not only represent a valuable model for end-stage disease
but also possess several qualities that make them amenable for
studying disease initiation and progression. Firstly, the time point
of the primary hit responsible for initiation of the disease can be
strictly controlled and subsequent changes monitored. Secondly,
monitoring changes within AML progression models has the
potential advantage to identify new effectors/collaborators, which
usually remain undetectable by approaches focussing only on frank
leukaemia. Thirdly, different AML mouse model systems are
available, which rely on transduction of distinct oncogenes with
varying latency periods, and hence provide a suitable platform to
identify shared pathways of general relevance for leukaemogenesis.
Mouse models therefore represent powerful tools to study
mechanisms of leukaemogenesis. Nevertheless, molecular targets
identified in mouse model systems need to be further validated in
human cells and xenotransplantation models to demonstrate
potential clinical applicability [36].
In this study, we specifically focussed on two broadly accepted
AML mouse models based on transplantation of stem/progenitor
cells retrovirally transduced with the oncogenic fusion-proteins MLL-
ENL and MOZ-TIF2, respectively [6,7,20]. The cell of origin for
leukaemic transformation is still a matter of ongoing debate. Our
selection of lin
-/kit
+ as control sample is in line with current evidence
where transduction of either self-renewing HSC or short-lived CMP
or GMP generated leukaemic cells with a similar immunophenotype
[6]. All three of these starting populations are highly enriched in our
of viable cells. Results from two independent experiments (mean 6 SD) are shown. C) Representative pictures of colony-formation in a competitive
proliferation assay performed in semi-solid culture. ME-I cells were transduced with PIG, Gata2 and DGata2 and 10
4 cells transferred to
methylcellulose after 36 hours. Images were taken after 4 days under bright-field (BF) and with GFP fluorescent light (GFP) and merged with 10x
magnifications (except section III, which was taken at 20x magnification). D) Cell-cycle analysis of GFP-positive and GFP-negative cells 36 hours after
transduction. The upper panel depicts a representative cell-cycle plot of GFP-positive and GFP-negative ME-I cells after transduction with PIG, Gata2
and DGata2. Note that GFP-positive and GFP-negative cells of each sample were analysed together without prior FACS-sorting, providing an internal
control for gating and settings of the instrument. X-axis shows PI fluorescence intensities, y-axis % of maximal counts. The lower panel depicts % of
total counts in sub-G0/G1 (sub), G0/G1, S and G2/M-phase as determined by the cell-cycle plot for GFP-positive and GFP-negative cells. Results from
two independent experiments (mean 6 SD) demonstrated statistically significant alterations for the Gata2 transduced cells (sub, p=0.97; G0/G1,
p=0.033; S, p=0.068; G2M, p=0.041; two-tailed t-test). E) Bar-chart of numbers of GFP-positive and GFP-negative colonies from C). Results from two
independent experiments (mean 6 SD) are shown. F) Comparison of GATA2 expression from published human AML microarray datasets performed
with Oncomine (http://www.oncomine.org) [62]. Boxes display median expression values and contain data from the 25
th to 75
th percentiles with the
bars representing the 10
th and 90
th percentiles respectively. Y-axis show log2 median centered ratios. The Valk et al dataset (GEO accession number:
GSE1159) [31] shown on the left shows relatively high GATA2 expression in CD34+ control cells when compared with bone marrow samples from 285
AML-patients (probe H00625, note that 10th percentile of the CD34 samples is higher than the 90th percentile of the AML samples, thus indicating a
significant difference in expression levels). The Heuser et al dataset (GEO accession number: GSE4137) [32] on the right similarly shows significantly
higher levels of GATA2 in CD34+ cells from two healthy controls compared to blood and bone marrow samples from 33 AML-patients prior induction
chemotherapy. G) Oncomine analysis of three independent gene expression datasets (GEO accession numbers: GSE1729, GSE425, GSE1159)
[31,33,34] demonstrates that GATA2 expression levels are not higher in AML subtypes characterised by minimal differentiation (FAB AML-M0).
doi:10.1371/journal.pone.0016330.g004
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-/kit
+ control population. Moreover, expression analysis of HSPC
TFs (such as HoxA9, Tal1, Scl, Lmo2) and myelomonocytic markers
(such as GM-Csfr, M-Csfr and G-Csfr) paralleled those described by
Cozzio et al [6] (see Figure S10 in Supporting Information S1). This
observation underlines the similarity of our model system with
previously published results and further validates the suitability of the
lin
-/c-kit
+ control population.
We and others have previously reported that promoters and
regulatory elements are enriched for H3K9ac marks [26,27].
Distinct histone marks, sometimes combined with DNA binding
proteins, have been used to identify potential regulatory regions
[37,38]. However, as long as regulatory elements are incompletely
identified and characterized, there is no single epigenetic mark ‘of
choice’ that can be considered the most appropriate to highlight
regulatory regions [39,40]. In both AML models, we observed
upregulation of abdominal HoxA-gene expression as expected.
Moreover, this was paralleled by substantially increased levels of
histone acetylation and therefore validated our experimental
approach of using regions of altered histone acetylation to
interrogate transcriptional control mechanisms that may underlie
leukaemia development. However, downstream effectors and/or
or parallel contributors other than a deregulated Hox-program are
required for leukaemia development [11,41]. The integrated
genome-wide approach used here provided a potential strategy to
identify some of these additional transcriptional events. Inference
of transcriptional control mechanisms from microarray expression
profiling data alone has been attempted in the past using
bioinformatic tools that typically search promoter regions or
collections of evolutionarily conserved sequence blocks for
overrepresented sequence motifs. When we examined our list of
differentially expressed genes using two of the most widely used
tools for this type of in silico analysis, oPOSSUM [42] only identified
the binding site for one of the 19 factors shown in Figure 3A (i.e.
Cebpa) and Webmotifs [43] failed to identify any significant motifs
at all (see Figure S11 in Supporting Information S1). By contrast,
our direct measurements of differential levels of histone acetylation
allowed us to select an experimentally informed set of candidate
regulatory regions that showed differential distribution of the
binding sites for 3 of the 4 differentially expressed factors including
the binding site for Gata2, the potential relevance of which we
went on to validate experimentally. Consistent with arguments put
forward in a recent review [40], integrated genomic approaches,
such as expression and ChIP-Seq profiling used here, provide a
much less arbitrary way to select regions for sequence motif
analysis than pure in silico approaches and should therefore be
widely applicable to study transcriptional dysregulation in disease.
In all current AML models, leukaemic cells display a somewhat
more mature surface marker phenotype compared with the cells
originally transduced, suggesting that expression changes alone
can not be taken as evidence for functional significance but need to
be followed up with specific experimentation. Integrated expres-
sion and ChIP-Seq profiling implicated downregulation of Gata2
as an important step during MLL-ENL and MOZ-TIF2 driven
leukaemogenesis. Gata2 is a major regulator of haematopoietic
stem cells during ontogeny [44] and a key component of wider
HSC regulatory networks [45,46,47]. High expression levels of
Gata2 are found in HSPC and down-regulation is required during
normal haematopoietic differentiation [48]. Interestingly, enforced
expression of Gata2 blocks normal haematopoiesis [49] and
induces quiescence in HSCs [50]. Gata2 therefore represents a
major regulator of HSPC homeostasis. Our finding that down-
regulationofGata2isa commonfeaturefortwoAMLmousemodel
systems suggests that abrogation of a Gata2-dependent transcrip-
tional program may contribute to leukaemogenic transformation
which is supported further by low GATA2 expression found in
large-scale human AML datasets. Acute lymphoid leukaemia
patient samples show overlapping, yet on average even lower levels
of GATA2 than AML (data not shown) suggesting that the
incompatibility of high GATA2 expression with leukaemia
development may extend beyond AML. Additionally, two
GATA-2 mutations (D341–346 and L359V), affecting the second
zinc-finger domain (see Figure S8B in Supporting Information S1)
and conferring either reduced or increased transcriptional activity,
respectively, have recently been described in patients progressing
from chronic to acute myeloidleukaemia.[51]. These findings arein
line with our conclusion that deregulated Gata2 expression is
involved in leukaemogenic progression, although, the exact
mechanisms remain still to be elucidated. Of note, high-level
ectopicexpression ofGata2inthemurinemyeloidcell line 416B did
not inhibit proliferation, but instead allowed the derivation of clonal
cell lines with a propensity for megakaryocytic differentiation [52],
thus suggesting that Gata2-mediated inhibition of proliferation is
context dependent. Importantly, our observation that MLL-ENL
transduced cells remain susceptible to Gata2 mediated induction of
cell-cycle arrest reveals a potential Achilles heel that could be
characteristic for MLL-ENL leukaemic cells and that warrants
further investigation.
Taken together, gene-expression and ChIP-Seq profiling
coupled with bioinformatic analysis and functional validation
allowed us to identify a potentially important, yet previously
unknown regulatory process, that operates during transcriptional
reprogramming in two mouse models of AML. Our results suggest
that down-regulation of Gata2 may contribute to leukaemogenic
transformation and that reactivation of Gata2 could be a novel
treatment strategy in patients with acute leukaemias. Moreover,
further analysis of the transcriptional repression program associ-
ated with the leukaemic phenotype may provide new mechanistic
insights into the efficacy of de-repressive epigenetic therapies such
as inhibition of histone deacetylases and DNA-methyltransferases
[53,54]. Finally, the integrated genome-wide approach employed
in this study should be readily adaptable to study transcrip-
tional reprogramming in other leukaemias as well as many solid
tumours.
Materials and Methods
Ethics statement
All animal experiments were performed under strict adherence
to UK home office regulations, licensed by the UK home office
under Project Licence PPL80/1900 and approved by the local
Cambridge University Licence Review Committee (LRC).
Cell samples
Wild-type bone marrow cells from Bl/6 mice were lineage
depleted following redblood cell lysis and purified using Fluorescent
Activated Cell Sorting (FACS) after staining with c-kit. The Factor-
Dependent Cells Patterson-Mix (FDCP-mix) were cultured as originally
described [21]. Previously described plasmids for MLL-ENL and
MOZ-TIF2 fusions with Neomycin selection marker or GFP were
used for in vitro replating experiments and in vivo transplantation
experiments [7,14,55]. Retroviral transduction of murine bone
marrow cells, serial replating and transplantation assays were
performed as previously described [7,14]. Factor-dependent cells
capable of sustained growth in liquid medium supplemented with
recombinant IL3 were generated by serial replating. ‘Leukaemic’
sample material was GFP-positive splenocytes collected from
secondary recipient mice upon frank leukaemia development.
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Biotin-labelled cRNA from three biological replicates was
generated from 250 ng of total RNA, hybridized onto Mou-
seWG-6 version 2 Expression Bead Chips (Illumina, San Diego,
CA) and data processed with the lumi Bioconductor package [56]
including variance-stabilizing transformation and quantile nor-
malization [57]. The human/mouse probesets for analysing
GATA2 gene expression were H00625 and ILMN_2612283
respectively. Two biological replicates per condition were used for
ChIP-Sequencing (ChIP-Seq) as previously described [18][58]
using polyclonal rabbit anti-acetyl histone H3K9 (Upstate).
Unique sequencing reads were mapped to the reference genome
build mm8 (February 2006), extended strand-specifically to
200 bp and displayed as density-plots using the UCSC genome-
browser.
Bioinformatic analysis
Gene expression data were deposited at the NCBI Gene
Expression Omnibus (accession number GSE25539). Differentially
expressed transcripts were determined using the limma Bioconductor
package at a False Discovery Rate (FDR) of #0.001 [59].
Unsupervised hierarchical clustering was performed using the
GenePattern platform (genepattern.broad.mit.edu) by applying
complete-linkage with Euclidian distances for samples and Pearson
correlations for probes. Gene Expression Dynamics Inspector (GEDI)
was used to visualize expression dynamics[60], Gene Set Enrichment
Analysis (GSEA) to identify enrichment for curated gene-sets (www.
broadinstitute.org/gsea/) [61] and Oncomine (www.oncomine.org)
to analyse Gata2 expression in leukaemia datasets [62].
ChIP-Seq peaks were identified using Findpeaks 3.1 at FDR
#0.05 [63] and used to define 400 bp-regions centered around the
highest point of significant peaks. Non-redundant regions were
scored by counting all 200 bp-extended reads within the region
and normalized to the total number of sequence-reads of the
corresponding sample. Significant changes of histone acetylation
between pair-wise comparisons of different conditions were
identified with the Cyber-T-test R-module by using all biological
replicates [64] and graphically displayed in kernel density
estimation plots. Significance thresholds were set at p,0.05 for
the most variable regions, which were further subdivided into
enriched and deprived regions. Motif analysis was performed using
TFBSsearch [65] with consensus motifs derived from the UniP-
robe and Jaspar databases. Expected frequencies were obtained by
applying a standard boot-strapping procedure (1000 random
samples) from the total number of peak-regions, providing a
random distribution of expected occurrences for each consensus-
motif for subsequent Z-score analysis.
Re-transduction of pre-leukaemic cells and competitive
proliferation assays in liquid or semi-solid culture
Full length Gata2 cDNA (MSCV-Gata2) and a 39-deletion
(MSCV-DGata2; 294 N-terminal amino-acids) were inserted into
pMSCV-Pgk-Puro-IRES-GFP (MSCV-PIG). Ecotropic viral super-
natants were produced and MLL-ENL pre-leukaemic cells
retransduced as previously described [7]. Competitive prolifera-
tion assays in liquid culture were performed by monitoring the
GFP-positive cell-fraction of the re-transduced MLL-ENL cells by
FACS-analysis over a 9-day time-course. Semi-solid assays were
performed by seeding 1610
4 retransduced MLL-ENL cells in
Methocult GF M3434 (StemCell Technologies) 36 hours after
infection. GFP-positive and negative colonies were counted after
four days with a Zeiss inverted 200M fluorescent microscope (Carls
Zeiss Ltd, Hertfordshire, UK), representative pictures taken with a
Hamamatsu Orca ER camera (Hamamatsu Photonics Ltd, Hertford-
shire, UK) and images processed with Improvision Openlab software
5.5.0 (Perkin Elmer, Waltham, Massachusetts).
Cell-Cycle and morphological analysis, AnnexinV and
Ki-67 staining
Cell cycle analysis and AnnexinV staining were performed as
previously described [66] and without prior sorting. FACS-analysis
was run in parallel for the GFP- positive and -negative cells and data
visualized by FlowJo (Tree Star Inc., Ashland, OR). Ki-67 staining
was performed 36 hours after infection on sorted, GFP-positive and -
negative cells following the manufacturers’ instructions (BD, 556026).
Supporting Information
Supporting Information S1 Supporting materials for the
manuscript "Genome-wide Analysis of Transcriptional Repro-
gramming in Mouse Models of Acute Myeloid Leukaemia" by
Bonadies et al, including the following: Supporting Figures S1 to
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